{
 "lastUpdated": "2026-10-16",
 "semaglutide": {
  "STEP_1": {
   "mean_weight_loss_pct": 14.9,
   "duration_weeks": 68,
   "dose_mg": 2.4
  },
  "STEP_5": {
   "mean_weight_loss_pct": 15.2,
   "duration_years": 2
  },
  "SELECT": {
   "mace_reduction_pct": 20,
   "hazard_ratio": 0.8,
   "n": 17604
  },
  "titration_mg": [
   0.25,
   0.5,
   1.0,
   1.7,
   2.4
  ],
  "regain_note": "STEP 1 extension: ~two-thirds of lost weight returned within a year of stopping"
 },
 "tirzepatide": {
  "SURMOUNT_1": {
   "5mg_pct": 15.0,
   "10mg_pct": 19.5,
   "15mg_pct": 20.9,
   "placebo_pct": 3.1,
   "duration_weeks": 72
  },
  "SURMOUNT_5": {
   "tirzepatide_pct": 20.2,
   "semaglutide_pct": 13.7
  },
  "SURMOUNT_4": {
   "note": "Withdrawal led to substantial regain"
  },
  "SURMOUNT_OSA": {
   "note": "First drug FDA-approved for obstructive sleep apnea"
  },
  "SURPASS": {
   "note": "Mounjaro diabetes; HbA1c reductions often 2%+ points"
  },
  "titration_mg": [
   2.5,
   5,
   7.5,
   10,
   12.5,
   15
  ]
 },
 "boxed_warning": "Thyroid C-cell tumors; contraindicated with personal/family history of MTC or MEN2",
 "note_2026_10": "SURMOUNT-1 figures are treatment-regimen estimand (20.9% at 15 mg; 22.5% under the efficacy estimand). SURMOUNT-5: 20.2% vs 13.7%. Results apply to the brand products studied, not to compounded versions."
}